PMID- 33386762
OWN - NLM
STAT- MEDLINE
DCOM- 20211213
LR  - 20211214
IS  - 1098-1101 (Electronic)
IS  - 0733-2459 (Linking)
VI  - 36
IP  - 3
DP  - 2021 Jun
TI  - Cardiovascular events in patients with familial hypercholesterolemia and 
      hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
PG  - 370-378
LID - 10.1002/jca.21872 [doi]
AB  - BACKGROUND: Lipoprotein apheresis (LA) is a safe method of reducing atherogenic 
      lipoproteins and improving cardiovascular (CV) outcomes. We aimed to assess the 
      reductions in low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) 
      [Lp(a)] levels in patients undergoing regular LA therapy and to evaluate its 
      influence on the incidence rate of adverse cardiac and vascular events (ACVE) and 
      major adverse cardiac events (MACE). METHODS: A longitudinal study in Poland 
      evaluated the prospective and retrospective observational data of 23 patients 
      with hyperlipoproteinaemia (a) [hyper-Lp(a)] and familial hypercholesterolemia 
      (FH), undergoing 1014 LA sessions between 2013 and 2020. Their pre- and 
      post-apheresis LDL-C and Lp(a) levels were assessed to calculate the acute 
      percent reductions. The time period used to evaluate annual rates of ACVE and 
      MACE before and after initiation of LA was matched in each patient. RESULTS: The 
      pre-apheresis LDL-C and Lp(a) concentrations were 155 (107-228) (mg/dL) (median 
      and interquartile range) and 0.56 (0.14-1.37) (g/L), respectively. LA therapy 
      resulted in a reduction of LDL-C to 50 (30-73.5) (mg/dL) and of Lp(a) to 0.13 
      (0.05-0.34) (g/L), representing a percent reduction of 70.0% and 72.7% for LDL-C 
      and Lp(a), respectively. We found a significant reduction in the annual rate of 
      ACVE (0.365[0.0-0.585] vs (0.0[0.0-0.265]; P = .047) and MACE (0.365[0.0-0.585] 
      vs 0.0[0.0-0.265]; P = .031). CONCLUSIONS: The findings of our study indicate 
      that LA treatment in patients with hyperlipoproteinaemia (a) and FH on maximally 
      tolerated lipid lowering therapies leads to a substantial reduction in LDL-C and 
      Lp(a) concentrations and lowers CV event rates in Polish patients.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Mickiewicz, Agnieszka
AU  - Mickiewicz A
AUID- ORCID: 0000-0003-1707-3807
AD  - Department of Cardiology I, Medical University of Gdansk, Gdansk, Poland.
FAU - Marlega, Joanna
AU  - Marlega J
AD  - Department of Cardiology I, Medical University of Gdansk, Gdansk, Poland.
FAU - Kuchta, Agnieszka
AU  - Kuchta A
AD  - Department of Clinical Chemistry, Medical University of Gdansk, Gdansk, Poland.
FAU - Bachorski, Witold
AU  - Bachorski W
AD  - Department of Cardiology I, Medical University of Gdansk, Gdansk, Poland.
FAU - Cwiklinska, Agnieszka
AU  - Cwiklinska A
AD  - Department of Clinical Chemistry, Medical University of Gdansk, Gdansk, Poland.
FAU - Raczak, Grzegorz
AU  - Raczak G
AD  - Department of Cardiology & Electrotherapy, Medical University of Gdansk, Gdansk, 
      Poland.
FAU - Gruchala, Marcin
AU  - Gruchala M
AD  - Department of Cardiology I, Medical University of Gdansk, Gdansk, Poland.
FAU - Fijalkowski, Marcin
AU  - Fijalkowski M
AD  - Department of Cardiology I, Medical University of Gdansk, Gdansk, Poland.
LA  - eng
GR  - ST 002-0085/07/182/Medical University of Gdansk/
PT  - Journal Article
DEP - 20210102
PL  - United States
TA  - J Clin Apher
JT  - Journal of clinical apheresis
JID - 8216305
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Lipoprotein(a))
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Component Removal/*methods
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Cholesterol, LDL/*blood
MH  - Humans
MH  - Hyperlipoproteinemia Type II/blood/complications/*therapy
MH  - Hyperlipoproteinemias/blood/complications/*therapy
MH  - Lipoprotein(a)/*blood
MH  - Longitudinal Studies
MH  - Middle Aged
OTO - NOTNLM
OT  - apheresis
OT  - cardiovascular events
OT  - familial hypercholesterolemia
OT  - lipoprotein (a)
EDAT- 2021/01/03 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/01/02 08:33
PHST- 2020/12/07 00:00 [revised]
PHST- 2020/07/21 00:00 [received]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/01/03 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/01/02 08:33 [entrez]
AID - 10.1002/jca.21872 [doi]
PST - ppublish
SO  - J Clin Apher. 2021 Jun;36(3):370-378. doi: 10.1002/jca.21872. Epub 2021 Jan 2.